@article{ffd9b17be9b44ddab8b1f2991bbc03c9,
title = "Negligible procedure-related dissemination risk of mucosal incision-assisted biopsy for gastrointestinal stromal tumors versus endoscopic ultrasound-guided fine-needle aspiration/biopsy",
abstract = "Background: Mucosal incision-assisted biopsy (MIAB) is a valuable alternative to endoscopic ultrasound-guided fine-needle aspiration/biopsy (EUS-FNAB) for sampling gastric subepithelial lesions (SELs). This study aimed to evaluate the potential risk of dissemination and impact on postoperative prognosis associated with MIAB, which has not yet been investigated. Methods: Study 1: A prospective observational study was conducted to examine the presence or absence and growth rate of tumor cells in gastric juice before and after the procedure in patients with SELs who underwent MIAB (n = 25) or EUS-FNAB (n = 22) between September 2018 and August 2021. Study 2: A retrospective study was conducted to examine the impact of MIAB on postoperative prognosis in 107 patients with gastrointestinal stromal tumors diagnosed using MIAB (n = 39) or EUS-FNAB (n = 68) who underwent surgery between January 2001 and July 2020. Results: In study 1, although no tumor cells were observed in gastric juice in MIAB before the procedure, they were observed in 64% of patients after obtaining samples (P < 0.001). In contrast, no tumor cells were observed in the gastric juice in EUS-FNAB before and after the procedure. In study 2, there was no significant difference in 5-year disease-free survival between MIAB (100%) and EUS-FNAB (97.1%) (P = 0.27). Conclusion: MIAB is safe, with little impact on postoperative prognosis, although the procedure releases some tumor cells after damaging the SEL{\textquoteright}s pseudocapsule.",
author = "Yosuke Minoda and Eikichi Ihara and Soichi Itaba and Yorinobu Sumida and Kazuhiro Haraguchi and Akira Aso and Takahiro Mizutani and Takashi Osoegawa and Mitsuru Esaki and Shuzaburo Nagatomo and Kei Nishioka and Kazumasa Muta and Xiaopeng Bai and Haruei Ogino and Nao Fujimori and Daisuke Tsurumaru and Kenoki Ohuchida and Hu Qingjiang and Eiji Oki and Hidetaka Yamamoto and Yoshihiro Ogawa",
note = "Funding Information: We would like to thank Dr. Junji Kishimoto in the Kyushu University Center for Clinical and Translational Research, for his help with the statistical analysis. Funding Information: Yosuke Minoda, Soichi Itaba, Yorinobu Sumida, Kazuhiro Haraguchi, Akira Aso, Takahiro Mizutani, Takashi Osoegawa, Mitsuru Esaki, Shuzaburo Nagatomo, Kei Nishioka, Kazumasa Muta, Xiaopeng Bai, Haruei Ogino, Nao Fujimori, Daisuke Tsurumaru, Kenoki Ohuchida, Hu Qingjiang, Eiji Oki, and Hidetaka Yamamoto have no conflict of interest. Eikichi Ihara received lecture fees from Takeda Pharmaceutical Co., Ltd. and belongs to an endowed course supported by the companies, including Ono pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Fujifilm Medical Co., Ltd., Terumo Corporation, FANCL Corporation, Ohga Pharmacy, and Abbott Japan, LLC. Yoshihito Ogawa conducts collaborative research with Fujifilm Medical Co., Ltd. and FANCL Corporation. The authors declare no other conflicts of interest in association with this study. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2023",
month = jan,
doi = "10.1007/s00464-022-09419-z",
language = "English",
volume = "37",
pages = "101--108",
journal = "Surgical endoscopy",
issn = "0930-2794",
publisher = "Springer New York",
number = "1",
}